Investment
Features
FeesSafety
Academy
More
Pluang+

Compare TransMedics Group Inc (TMDX) vs Weibo Corp (WB) Price & Performance

TransMedics Group IncTrade
Weibo CorpTrade

Price performance (Past 24H)

Key statistics

TransMedics Group Inc vs Weibo Corp — how do they compare? TransMedics Group Inc trades at $87.08 (market cap $3.10B), while Weibo Corp trades at $7.87 (market cap $1.93B). The key difference: TransMedics Group Inc is the larger of the two by market cap, and Weibo Corp pays a 7.75% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.

TMDXWB
Market Cap
$3.10B$1.93B
Sector
TechnologyMedia
52-Week High
$150.42$12.83
52-Week Low
$61.99$7.20
Enterprise Value
$3.49B$1.20B
Dividend Yield
7.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

TransMedics Group Inc

TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.

The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.

Weibo Corp

Weibo (WB) trades at $7.76, down 2.82% amid bearish technical signals, though valuation metrics appear attractive with a P/E of 5.5 and P/B of 0.5. The company maintains strong profitability with 21.15% net margins and $449M net income in 2025, but has missed earnings expectations for three consecutive quarters. Cash flow trends show volatility, with 2024 net cash flow negative $694M despite solid operational performance.

The stock presents a value opportunity given deep discount to balance sheet value, but faces competitive pressures and user engagement challenges. Analyst sentiment is mixed with 45% buy ratings, while technical indicators suggest near-term weakness. Key risks include Chinese regulatory environment and competition from Douyin/WeChat.

Returns comparison

Trailing returns across standard periods

About TransMedics Group Inc

TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.

Read more on TMDX

About Weibo Corp

Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.

Read more on WB